UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 12, 2018

 

INNOVATION PHARMACEUTICALS INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

 

001-37357

 

30-0565645

(State or Other Jurisdiction

of Incorporation)

 

(Commission
File Number)

 

(IRS Employer

Identification No.)

 

100 Cummings Center,
Suite 151-B Beverly, Massachusetts

 

01915

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (978) 921-4125

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 
 
 
 

 

Item 8.01 Other Events.

 

On November 12, 2018, Innovation Pharmaceuticals Inc. (the “Company”) issued 250 shares of its Series B 5% convertible preferred stock (the “preferred stock”), for aggregate gross proceeds of $245,625, upon exercise of warrants issued by the Company in October 2018. The exercise of the warrants was pursuant to a provision in the warrants that permitted the Company to compel the warrant holders to exercise up to $250,000 of the warrants 30 days after the initial closing of the sale of the preferred stock.

 

As of the close of business on November 12, 2018, 1,400 shares of preferred stock were outstanding, and 171,282,118 shares of the Company’s common stock were outstanding. As of the close of business on November 2, 2018, 169,231,216 shares of the Company’s common stock were outstanding. The Company had previously reported incorrectly in its Form 10-Q for the quarter ended September 30, 2018 that 163,676,190 shares of its common stock were outstanding as of November 2, 2018.

 

 
2
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  INNOVATION PHARMACEUTICALS INC.
       
Dated: November 13, 2018 By: /s/ Leo Ehrlich

 

Name:

Leo Ehrlich  
  Title: Chief Executive Officer and Chief Financial Officer  

 

 

 
3

 

Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.